ROS1 and non-small cell lung carcinoma: In particular, Tremblay et al. published a paper in which they produced a clinical trial-to-clinical trial simulated treatment comparison (STC) using data from the regulatory approval-supporting trials for crizotinib and entrectinib to compare the efficacy of crizotinib and entrectinib in ROS1-positive non small cell lung cancer [56].